Stock Events

Stock Events

Nextcure 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-9.67
-6.58
-3.49
-0.4
Expected EPS
-1.5789972
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-105.56MNet Income

Analyst Ratings

$13.66Average Price Target
The highest estimate is 13.66.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 2US0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is involved in gene editing for cancer therapies, a direct competitor in innovative cancer treatments.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a broad oncology portfolio, competing in the cancer treatment market.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong presence in oncology and cell therapy, making it a competitor in cancer treatment.
Merck
MRK
Mkt Cap214.76B
Merck & Co. is known for its cancer drug Keytruda, directly competing with Nextcure's cancer immunotherapies.
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Bristol-Myers Squibb, with its range of oncology products, competes in the cancer immunotherapy market.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including oncology, competing with Nextcure in cancer treatment.

About

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Show more...
CEO
ISIN
US65343E2072
WKN
000A41AKJ

Listings

XNAS
US
NXTC
F
DE
2US0.F
BOATS
BOATS
NXTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Nextcure stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Nextcure stocks are traded under the ticker 2US0.F.
Is Nextcure stock price growing?▼
2US0.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Nextcure has showed a +8.09% increase.
When is the next Nextcure earnings date?▼
Nextcure is going to release the next earnings report on April 30, 2026.
What were Nextcure earnings last quarter?▼
2US0.F earnings for the last quarter are -0.4 EUR per share, whereas the estimation was -1.97 EUR resulting in a +79.91% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Nextcure revenue for the last year?▼
Nextcure revenue for the last year amounts to 0 EUR.
What is Nextcure net income for the last year?▼
2US0.F net income for the last year is -105.56M EUR.
When did Nextcure complete a stock split?▼
The last stock split for Nextcure was on July 14, 2025 with a ratio of 1:12.